These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 21655476

  • 41. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
    Hirai Y, Yoshimasu T, Oura S, Tamaki T, Ota F, Nakamura R, Shimizu Y, Naito K, Ota M, Miyasaka M, Okamura Y, Nakamura Y, Yasuoka H, Kodama R.
    Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
    [Abstract] [Full Text] [Related]

  • 42. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM.
    Clin Cancer Res; 2004 Jun 01; 10(11):3794-9. PubMed ID: 15173087
    [Abstract] [Full Text] [Related]

  • 43. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May 01; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 44. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.
    Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ.
    Lung Cancer; 2005 Nov 01; 50(2):211-9. PubMed ID: 16169122
    [Abstract] [Full Text] [Related]

  • 45. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
    De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):159-65. PubMed ID: 23645290
    [Abstract] [Full Text] [Related]

  • 46. DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients.
    Schena M, Guarrera S, Buffoni L, Salvadori A, Voglino F, Allione A, Pecorari G, Ruffini E, Garzino-Demo P, Bustreo S, Consito L, Bironzo P, Matullo G.
    DNA Repair (Amst); 2012 Apr 01; 11(4):374-80. PubMed ID: 22284908
    [Abstract] [Full Text] [Related]

  • 47. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 01; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 48. ERCC1 (excision repair cross-complementation group 1) expression as a predictor for response of neoadjuvant chemotherapy for FIGO stage 2B uterine cervix cancer.
    Park JS, Jeon EK, Chun SH, Won HS, Lee A, Hur SY, Lee KH, Bae SN, Yoon SC, Hong SH.
    Gynecol Oncol; 2011 Feb 01; 120(2):275-9. PubMed ID: 21093896
    [Abstract] [Full Text] [Related]

  • 49. ERCC1 measurements in clinical oncology.
    Reed E.
    N Engl J Med; 2006 Sep 07; 355(10):1054-5. PubMed ID: 16957152
    [No Abstract] [Full Text] [Related]

  • 50. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H.
    Lung Cancer; 2008 Mar 07; 59(3):377-84. PubMed ID: 17905465
    [Abstract] [Full Text] [Related]

  • 51. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.
    J Clin Oncol; 2007 Jul 01; 25(19):2741-6. PubMed ID: 17602079
    [Abstract] [Full Text] [Related]

  • 52. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD, Waldstrøm M, Jakobsen A.
    Int J Gynecol Cancer; 2009 Jul 01; 19(5):820-5. PubMed ID: 19574766
    [Abstract] [Full Text] [Related]

  • 53. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.
    Lung Cancer; 2008 Jan 01; 59(1):95-104. PubMed ID: 17889401
    [Abstract] [Full Text] [Related]

  • 54. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A, Nakayama M, Kakuta Y, Abe T, Hatano K, Mukai M, Nagahara A, Nakai Y, Oka D, Takayama H, Yoshioka T, Hoshida Y, Itatani H, Nishimura K, Nonomura N.
    Clin Cancer Res; 2011 Apr 15; 17(8):2561-9. PubMed ID: 21177407
    [Abstract] [Full Text] [Related]

  • 55. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival.
    Zimling ZG, Sørensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E.
    J Thorac Oncol; 2012 Jan 15; 7(1):249-56. PubMed ID: 22031231
    [Abstract] [Full Text] [Related]

  • 56. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer.
    Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F, Maehara Y.
    Int J Cancer; 2007 Aug 15; 121(4):895-900. PubMed ID: 17417781
    [Abstract] [Full Text] [Related]

  • 57. Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy.
    Milovic-Kovacevic M, Srdic-Rajic T, Radulovic S, Bjelogrlic S, Gavrilovic D.
    J BUON; 2011 Aug 15; 16(4):708-14. PubMed ID: 22331726
    [Abstract] [Full Text] [Related]

  • 58. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
    Rybárová S, Muri J, Hodorová I, Vecanová J, Benický M, Piovarči D, Janík P, Mihalik J, Mirossay L.
    Klin Onkol; 2012 Aug 15; 25(5):370-4. PubMed ID: 23102199
    [Abstract] [Full Text] [Related]

  • 59. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2008 Aug 15; 18(4):702-10. PubMed ID: 17961161
    [Abstract] [Full Text] [Related]

  • 60. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
    Jiang H, Wang H, Wang S, Pei Z, Fu Z, Fang C, Wang J, Lu Q, Wang E, Li J.
    Mol Med Rep; 2015 May 15; 11(5):3523-32. PubMed ID: 25573098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.